When Kenneth Frazier became chief executive of Merck & Co. in early 2011, he staunchly defended the company's vaunted drug-research laboratories, vowing to stay the course on R&D spending while some rivals were retrenching.

Now two and a-half years and 10 or so research setbacks later, the pressure for better results has mounted.

...